PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA. (23rd June 2022) - Soussain, C.; Grommes, C.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B.; Ding, Z.; Yusuf, I.; Rose, M.; Steinberg, M.; et al.